Skip to main content

Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms

Active, not recruiting · Not applicable · NCT03728985

Conditions: Thoracoabdominal Aortic Aneurysm

At a glance

Research payments reported, 2025
$285,147
U.S. investigators named
40
Sites paid
37
Planned or actual enrollment
102

About the trial

Sponsor
W.L.Gore & Associates
Tested
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis (device)
Dates
Started 2019-06-17; completion 2030-01
Results posted
Yes

Prospective, non-randomized, , multicenter study with two independent arms: * Primary Study Arm - TAAA and Pararenal aneurysms requiring only TAMBE System. Hypothesis-driven analysis. * Up to 65 additional subjects may be implanted in Continued Access Phase under the Primary Study Arm only * Secondary Study Arm - TAAA requiring TAMBE System and CTAG Device(s). Non hypothesis-driven analysis. Minimum: 122 implanted subjects. Maximum: 202 implanted subjects with up to 65 additional subjects implanted in Continued Access (Primary Study arm)

From ClinicalTrials.gov, last updated 2026-09-02. Full record, eligibility and contacts (opens in a new tab)

Industry funding

W. L. Gore & Associates, Inc. reported $285,147 in research payments for this study in 2025 (147 payments).

Products named: Product in Development

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.